Retinopathy of prematurity (ROP), a retinal vascular disease of premature infants, continues
to be a major cause of preventable childhood blindness all over the world. The incidence of …

The publication of the BEAT-ROP study of bevacizumab (Avastin) treatment for Zone I and II
retinopathy of prematurity (ROP) has raised hopes that there might now be a simpler …

Background Retinopathy of prematurity is a leading cause of childhood blindness
worldwide. Peripheral retinal ablation with conventional (confluent) laser therapy is …

Purpose To determine incidence, risk factors, risk period, and characteristics of recurrent
retinopathy of prematurity (ROP) treated by intravitreal bevacizumab (IVB) monotherapy …

Purpose: To report reactivation rate after bevacizumab treatment for retinopathy of
prematurity (ROP) in eyes with classic ROP (CROP) versus aggressive posterior ROP …

Purpose To investigate the anatomic outcomes and influencing factors of ranibizumab in the
treatment of retinopathy of prematurity (ROP). Design Retrospective case series. Participants …

Intravitreal injection of bevacizumab has been shown to satisfactorily treat retinopathy of
prematurity; nevertheless, the safety of antivascular endothelial growth factor therapy in …

The review aims to evaluate the uses of conventional laser therapy and intravitreal injection
of various anti-VEGF in terms of efficacy and side effects for the treatment of retinopathy of …

Retinopathy of prematurity (ROP) is a leading cause of childhood blindness worldwide.
Although laser photocoagulation remains the gold standard for treating threshold and …

Purpose: To evaluate angiographic findings in neonates up to 150 weeks postmenstrual age
who received intravitreal ranibizumab for primary treatment of Type 1 retinopathy of …